Nicotinic acid - Familial hypercholesterolaemia
You are here : Home > Formulary Search > Nicotinic acid - Familial hypercholesterolaemia
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
Guidelines (National)
Policy Statement
PAD Profile
ChemicalSubstance :
Nicotinic acid
Indication :
Familial hypercholesterolaemia
Group Name :
Keywords :
high cholesterol, raised cholesterol, lipid lowering, lipid modification, hyperlipidaemia, FH
Brand Names Include :
Niacin, Niaspan
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Nicotinic acid is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Familial hypercholesterolaemia.
- No records returned.
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
Nicotinic acid is no longer available as a licensed product in the UK (Niaspan license withdrawn in June 2011), and other licensed treatments are available for FH. Therefore, the PCN recommends nicotinic acid is classified as BLACK on the traffic light system for this indication.
Patients that are currently being treated with Nicotinic Acid for the treatment of familial hypercholesterolaemia* should have their treatment reviewed. It should be a shared decision between the NHS clinician and the patient as to whether it is appropriate for the treatment to be stopped.
*Some patient’s may have been initiated on Nicotinic Acid prior to NICE recommendations
NOTE - NICE CG71 (updated in July 2016) recommends patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration of treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
At the time of publication of CG71 nicotinic acid was available as a licensed product.
Patients that are currently being treated with Nicotinic Acid for the treatment of familial hypercholesterolaemia* should have their treatment reviewed. It should be a shared decision between the NHS clinician and the patient as to whether it is appropriate for the treatment to be stopped.
*Some patient’s may have been initiated on Nicotinic Acid prior to NICE recommendations
NOTE - NICE CG71 (updated in July 2016) recommends patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration of treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
At the time of publication of CG71 nicotinic acid was available as a licensed product.